arct-810
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04416126)
Timeline
Indications
Mechanism of action
- Ornithine decarboxylaseSupplementation
Ornithine decarboxylase supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06488313 | Phase 2 | Jun 10, 2024 | Arcturus Therapeutics |
| NCT05526066 | Phase 2 | Jul 6, 2022 | Arcturus Therapeutics |
| NCT04442347 | Phase 1 | Oct 31, 2020 | Arcturus Therapeutics |
| NCT04416126 | Phase 1 | Jun 30, 2020 | Arcturus Therapeutics, Auckland Clinical Studies |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arcturus Therapeutics | For profit | 4 | 4 | 2 | 2020 |
| Auckland Clinical Studies | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1